Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BAX
stocks logo

BAX

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
2.82B
-25.95%
0.608
-10.52%
2.91B
+7.85%
0.647
-19.18%
3.04B
+10.56%
0.713
+22.96%
Estimates Revision
The market is revising Upward the revenue expectations for Baxter International Inc. (BAX) for FY2025, with the revenue forecasts being adjusted by 1.54% over the past three months. During the same period, the stock price has changed by -11.48%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.54%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+1.13%
In Past 3 Month
Stock Price
Go Down
down Image
-11.48%
In Past 3 Month
9 Analyst Rating
up Image0
Wall Street analysts forecast BAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BAX is 35.75 USD with a low forecast of 28.00 USD and a high forecast of 41.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
5 Hold
1 Sell
Hold
up Image0
Current: 30.620
sliders
Low
28.00
Averages
35.75
High
41.00
up Image0
Current: 30.620
sliders
Low
28.00
Averages
35.75
High
41.00
Morgan Stanley
Patrick Wood
Sell
Maintains
$30 → $28
2025-05-05
Reason
Morgan Stanley
Patrick Wood
Price Target
$30 → $28
2025-05-05
Maintains
Sell
Reason
Medical Supplies & Devices Analyst Marcus holds a Post-1Q Investor Relations conference call with SVP of Investor Relations Trachtman on May 2 at 11 am hosted by JPMorgan.
Wells Fargo
Larry Biegelsen
Hold
Maintains
$36 → $33
2025-05-02
Reason
Wells Fargo
Larry Biegelsen
Price Target
$36 → $33
2025-05-02
Maintains
Hold
Reason
Wells Fargo lowered the firm's price target on Baxter to $33 from $36 and keeps an Equal Weight rating on the shares. The firm notes the company delivered a good start to FY25 with strong Novum IQ adoption, early recovery in IV solutions, and resilient capital trends. On tariffs, Baxter will absorb $60M-$70M headwind to FY25 margins/EPS, Wells adds.
Barclays
Matt Miksic
Buy
Maintains
$39 → $41
2025-03-10
Reason
Barclays
Matt Miksic
Price Target
$39 → $41
2025-03-10
Maintains
Buy
Reason
Barclays raised the firm's price target on Baxter to $41 from $39 and keeps an Overweight rating on the shares. The firm updated its model to reflect the company's 2025 guidance and recent commentary.
Goldman Sachs
David Roman
Strong Buy
Initiates
$42
2025-02-26
Reason
Goldman Sachs
David Roman
Price Target
$42
2025-02-26
Initiates
Strong Buy
Reason
Goldman Sachs reinstated coverage of Baxter with a Buy rating and $42 price target. Over the next several quarters, the firm expects the company to make "meaningful progress" toward margin and cash flow improvement, driving its earnings above consensus estimates. Baxter's risk/reward is skewed positively at current levels, the analyst tells investors in a research note.
JP Morgan
Robbie Marcus
Hold
Maintains
$38 → $36
2025-02-21
Reason
JP Morgan
Robbie Marcus
Price Target
$38 → $36
2025-02-21
Maintains
Hold
Reason
Barclays
Matt Miksic
Buy
Initiates
$39
2025-02-20
Reason
Barclays
Matt Miksic
Price Target
$39
2025-02-20
Initiates
Buy
Reason
Barclays reinstated coverage of Baxter with an Overweight rating and $39 price target. The firm updated its sales projections to reflect the company's continuing operations, which exclude sales of renal care in 2024, 2025 and beyond. The analyst believes the macro headwinds facing Baxter are largely discounted at current share levels. The stock's substantial year-to-date underperformance and "significant" deal-related financial flexibility position the shares to outperform relative to the market, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Baxter International Inc (BAX.N) is 12.34, compared to its 5-year average forward P/E of 17.29. For a more detailed relative valuation and DCF analysis to assess Baxter International Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PE
17.29
Current PE
12.34
Overvalued PE
21.85
Undervalued PE
12.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
12.76
Current EV/EBITDA
10.04
Overvalued EV/EBITDA
15.05
Undervalued EV/EBITDA
10.46

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PS
2.11
Current PS
1.37
Overvalued PS
2.97
Undervalued PS
1.25

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress areBuying! The buying amount has increased100%over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

BAX News & Events

Events Timeline

(ET)
2025-05-01
08:01:31
Baxter narrows FY25 adjusted EPS view to $2.47-$2.55 from $2.45-$2.55
select
2025-05-01
08:00:27
Baxter sees Q2 adjusted EPS 59c-63c, consensus 61c
select
2025-05-01
07:59:21
Baxter reports Q1 adjusted EPS 62c, consensus 48c
select
Sign Up For More Events
Sign Up For More Events

News

Preview
8.0
06-11NASDAQ.COM
Notable Tuesday Option Activity: APP, CVX, BAX

  • Chevron Corporation Options Trading: Chevron saw significant options trading with 56,285 contracts, particularly for the $147 strike call option expiring June 13, 2025, which accounted for a notable portion of its average daily trading volume.

  • Baxter International Options Activity: Baxter International experienced high options trading as well, with 21,646 contracts traded, especially for the $32.50 strike call option expiring July 18, 2025, representing a large percentage of its average daily volume.

Preview
4.5
06-03NASDAQ.COM
Monday Sector Laggards: Consumer Products, Healthcare

  • Consumer Products Sector Performance: The Consumer Products sector is the worst performing on Monday, with a 1.1% loss; General Motors and Ford are notably down 4.6% and 4.5%, respectively, while the iShares U.S. Consumer Goods ETF is down 0.8% but up 8.89% year-to-date.

  • Healthcare Sector Performance: The Healthcare sector follows closely with a 0.8% loss, led by Molina Healthcare and Baxter International down 3.2% and 3.1%; the Health Care Select Sector SPDR ETF is down 0.4% today and 3.58% year-to-date.

Preview
5.0
05-19MarketWatch
This stock trader called a bottom for the S&P 500. Here’s what he’s saying now.

  • Warren Buffett's Retirement: Warren Buffett announced his retirement as chief executive of Berkshire Hathaway at the end of the year, signaling the end of an era characterized by traditional market fundamentals.

  • Market Volatility Concerns: Analysts express concerns about increased market volatility due to unpredictable influences from current political leadership, which could significantly impact investment portfolios.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Baxter International Inc (BAX) stock price today?

The current price of BAX is 30.62 USD — it has decreased -2.36 % in the last trading day.

arrow icon

What is Baxter International Inc (BAX)'s business?

Baxter International Inc., through its subsidiaries, provides a portfolio of essential healthcare products. The Company’s Medical Products and Therapies segment includes sales of sterile IV solutions, infusion systems, administration sets, parenteral nutrition therapies and surgical hemostat, sealant and adhesion prevention products. Its Healthcare Systems and Technologies segment includes connected care solutions and collaboration tools, including smart bed systems, patient monitoring systems and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space, including surgical video technologies and precision positioning devices. Its Pharmaceuticals segment includes specialty injectable pharmaceuticals, inhaled anesthesia and drug compounding. Its Kidney Care segment includes chronic and acute dialysis therapies and services, including peritoneal dialysis, hemodialysis, continuous renal replacement therapies (CRRT) and other organ support therapies.

arrow icon

What is the price predicton of BAX Stock?

Wall Street analysts forecast BAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BAX is 35.75 USD with a low forecast of 28.00 USD and a high forecast of 41.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Baxter International Inc (BAX)'s revenue for the last quarter?

Baxter International Inc revenue for the last quarter amounts to 2.63B USD, increased 5.42 % YoY.

arrow icon

What is Baxter International Inc (BAX)'s earnings per share (EPS) for the last quarter?

Baxter International Inc. EPS for the last quarter amounts to 0.25 USD, increased 257.14 % YoY.

arrow icon

What changes have occurred in the market's expectations for Baxter International Inc (BAX)'s fundamentals?

The market is revising Upward the revenue expectations for Baxter International Inc. (BAX) for FY2025, with the revenue forecasts being adjusted by 1.54% over the past three months. During the same period, the stock price has changed by -11.48%.
arrow icon

How many employees does Baxter International Inc (BAX). have?

Baxter International Inc (BAX) has 60000 emplpoyees as of June 14 2025.

arrow icon

What is Baxter International Inc (BAX) market cap?

Today BAX has the market capitalization of 15.71B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free